Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Arvinas Reports LowerthanExpected Quarterly Losses and Positive Financial Outlook

Elaine Mendonca by Elaine Mendonca
February 27, 2024
in Breaking News
0
Biotechnology Stock Exchange
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Arvinas recently announced their financial results for the quarter ending on February 27, 2024. The company reported a loss of $(2.53) per share, which was significantly lower than the analyst consensus estimate of $(1.28) by 97.66%. This marks a 62.18% decrease from the previous year’s loss of $(1.56) per share.

With a cash balance of $1,266.5 million, Arvinas is projected to have enough funds to sustain operations until 2027. Over the past four quarters, the company has recorded a net income of -$282.50 million and generated -$5.53 earnings per share. In the most recent quarter, the reported EPS was ($1.18), surpassing analysts’ expectations of ($1.58) by $0.40. Despite slightly lower than anticipated quarterly revenue of $34.60 million, compared to the expected $39.58 million, Arvinas remains optimistic about its financial outlook.

ARVN Stock Price Surges on February 27, 2024: Investors Advised to Monitor Movement Carefully

On February 27, 2024, ARVN stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. The price of ARVN shares increased by $1.79 since the market last closed, representing a 3.81% rise. The stock closed at $48.79, which is a relatively high price compared to its recent trading history. However, it is worth noting that the stock has since dropped $0.79 in pre-market trading. Overall, ARVN stock had a positive performance on February 27, 2024, with a significant increase in price. Investors should continue to monitor the stock’s movements and consider their investment strategy based on their own financial goals and risk tolerance.

ARVN Stock Performance: Mixed Results in Financial Report for 2024

On February 27, 2024, ARVN stock experienced mixed performances as the company reported its financial results for the past year and the most recent quarter. According to data from CNN Money, ARVN’s total revenue for the past year was $131.40 million, representing an impressive 181.37% increase compared to the previous year. However, the total revenue for the most recent quarter was $34.60 million, showing a significant decrease of 36.51% compared to the previous quarter.

In terms of net income, ARVN reported a net loss of $282.50 million for the past year, which was a decrease of 47.91% compared to the previous year. On the other hand, the net loss for the most recent quarter was $64.00 million, showing a slight increase of 3.9% compared to the previous quarter.

Earnings per share (EPS) for ARVN also showed mixed results. The EPS for the past year was -$5.31, which was a decrease of 39.01% compared to the previous year. However, the EPS for the most recent quarter was -$1.18, showing a modest increase of 5.15% compared to the previous quarter.

Overall, ARVN stock performances on February 27, 2024, were impacted by the mixed financial results reported by the company. While the significant increase in total revenue for the past year is a positive sign, the decrease in revenue and net income for the most recent quarter may have caused some concern among investors. The slight improvement in EPS for the most recent quarter could provide some reassurance to investors, but it remains to be seen how ARVN will perform in the coming quarters. Investors should closely monitor the company’s financial performance and any updates from ARVN to make informed decisions about their investments in the stock.

Tags: ARVN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
lithium-ion-batteries-750x375

Investment Boom: How Lithium Exploration Projects Are Shaping North America’s Economic Landscape

Biotechnology Trading online

Thoughtworks Holding NASDAQ TWKS Disappoints Investors with Q4 Earnings Miss

CRWD stock news

PAR Technology Reports Quarterly Losses and Revenue Growth

Recommended

Fiserv Stock

Fiserv Shares Struggle to Gain Traction Amid Investor Doubts

3 weeks ago
Cooper-Standard Stock

Cooper-Standard Shares Plunge on Disappointing Earnings Report

3 months ago
Volatus Aerospace Stock

Volatus Aerospace Expands Defense and Environmental Technology Operations

5 months ago
FCBC stock news

Symmetry Partners LLC Acquires Significant Position in Carnival Co. & plc, Expresses Optimism for Future Growth

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Trending

Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

by Rodolfo Hanigan
February 7, 2026
0

Medical device company Embecta reported financial results for the first quarter of fiscal year 2026 on Thursday,...

Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test
  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com